查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年人类胚胎干细胞市场预测：按类型、来源、用途和地区分類的全球分析
市场调查报告书
商品编码
1371999

2030 年人类胚胎干细胞市场预测：按类型、来源、用途和地区分類的全球分析

Human Embryonic Stem Cells Market Forecasts to 2030 - Global Analysis By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Multipotent Stem Cells, Oligopotent Stem Cells, Unipotent Stem Cells and Other Types), Source, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2023年全球人类胚胎干细胞市场规模为18亿美元，预计在预测期内将以11.2%的年复合成长率成长，到2030年达到38亿美元。

人类胚胎干细胞是一种多功能细胞，由人类胚胎胚囊（通常是受精后 5 至 7 天）的内细胞团产生。这种细胞几乎可以长成人体的任何细胞。它们不仅在人类早期发育中发挥重要作用，而且在再生医学和研究中也具有巨大的应用潜力。为了确保使用人类胚胎干细胞的疗法的有效性和安全性，严格的品管程序以及对其製造和部署的安全性评估至关重要。

2022 年 8 月发表的一篇 DVC Stem报导证实，干细胞治疗帕金森氏症的目标是用健康、未分化的干细胞取代受损的脑细胞。

技术进步不断进步

人类胚胎干细胞市场极大地受益于技术进步。这些进展显着提高了人类胚胎干细胞的功效、安全性和效用，使其成为潜在研究和治疗应用更具吸引力的选择。三维（3D）培养模型的发展使研究人员能够更准确地重建人体内细胞的自然环境。因此，人类胚胎干细胞已改善分化为用于再生治疗的特定细胞类型。借助 CRISPR-Cas9 等技术创新，现在可以精确编辑 hESC 基因组，从而彻底改变了基因编辑领域。因此，上述所有要素都在推动市场成长。

对使用胚胎干细胞的道德问题的担忧

探索胚胎干细胞（ESC）治疗潜力的研究与许多道德困境有关，包括杀死人类胚胎。由于缺乏适当的政府立法来规范胚胎干细胞治疗方法开发的支持，最终可能会在一定程度上限制市场的成长。由于该领域法律的复杂性，需要进一步的联邦立法来帮助研究人员、科学家和製药公司开发并加速胚胎干细胞治疗方法的商业化。

慢性病增加

糖尿病、心血管疾病、神经系统疾病和自体自体免疫疾病等慢性疾病的罹患率不断上升，增加了对有效治疗方法的需求。这些疾病通常涉及永久性组织损伤，可以透过基于人类胚胎干细胞的治疗方法来治疗。慢性疾病患者经常出现组织劣化和器官功能障碍，再生医学技术利用它们来修復、替换和再生受损的组织和器官，从而解决慢性病的长期影响，是一种有用的资源。临床研究已经开始确定使用人类胚胎干细胞来治疗某些慢性疾病的安全性和有效性。

免疫排斥倾向

免疫排斥会导致源自人类胚胎干细胞的细胞疗法失败。如果接受者的免疫系统将移植的细胞识别为外来细胞，则移植的细胞可能会被攻击和杀死，从而导致治疗无效，并限制人类胚胎干细胞治疗的长期益处。益处可能有限。即使最初的植入是有效的，持续的免疫反应也会导致移植细胞逐渐流失，缩短治疗效果的寿命，从而阻碍市场成长。

COVID-19 的影响

这场大流行扰乱了该研究所的研究项目，特别是干细胞项目。一些研究机构的暂时关闭或缩减阻碍了人类胚胎干细胞的研发和临床试验。此外，实验室关闭、病患招募挑战和安全问题减缓了这些临床试验的进展，并更加重视医学研究和治疗开发的安全性和有效性。因此，使用人类胚胎干细胞的药物将接受更彻底的安全评估，这可能会阻碍市场成长。

预计全能干细胞领域在预测期内将是最大的。

全能干细胞领域是一种特殊类型的干细胞，具有有利的生长潜力，因为人体内所有类型的细胞，包括胚胎外和胚胎组织，都可以由这些细胞形成。全能干细胞与全能干细胞的不同之处在于，全能干细胞可以发展成除胚外组织外的所有体细胞。使用这些细胞的研究有助于了解全能干细胞如何发展成不同的细胞类型。

干细胞生物学研究领域预计在预测期内将出现最高的年复合成长率。

干细胞生物学研究领域预计在预测期内年复合成长率最高。各种类型的干细胞也用于医学。许多生物製药公司最近对这些化合物进行了大量研究，这些化合物对多种疾病有大量的阶段用途，包括癌症和神经系统疾病。随着帕金森氏症和癌症等疾病发生率的增加，干细胞生物学研究预计未来将进一步发展。由于这些原因，预计所研究的市场将在预测期内显着增长。

比最大的地区

除了政府对药物研发、医疗保健投资以及在药物研发技术开发的先进基础设施方面取得进展的重视外，由于该地区多家公司扩大发展战略，北美正在经历快速增长。在预测期内占据最大的市场占有率。此外，药物研究和相关临床研究的严格法规规则预计将提振市场。在美国，生物製药製造商正在推出生物製药和生物相似药产品，这是预计支持市场扩张的另一个要素。

复合年复合成长率最高的地区：

由于欧洲对人类胚胎干细胞用于研究和治疗的使用有严格的法律法规，预计在预测期内复合年复合成长率最高。使用干细胞开发和核准药物受到国家法规机构和欧洲药品管理局 (EMA) 的法规。例如，在欧洲，利用人类胚胎干细胞治疗多种疾病的临床研究已经且目前正在进行中，包括脊髓损伤、心臟病和退化性疾病。这些临床试验的目的是评估基于干细胞的治疗的有效性和安全性。该地区学术机构、生物技术公司和医疗机构之间的合作很常见，以推进人类胚胎干细胞的研究和实用化，从而推动市场发展。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球人类胚胎干细胞市场：依类型

  • 全能干细胞
  • 多功能细胞
  • 多能干细胞
  • 寡能干细胞
  • 单能干细胞
  • 其他类型

第6章全球人类胚胎干细胞市场：依来源分类

  • 骨髓
  • 成人身体组织
  • 胚胎组织
  • 胎儿组织
  • 分化的体细胞
  • 其他资讯来源

第7章全球人类胚胎干细胞市场：依用途

  • 干细胞生物学研究
  • 再生医学
  • 人体组织工程
  • 毒性试验
  • 血液疾病的治疗
  • 心血管疾病的治疗
  • 其他用途

第8章全球人类胚胎干细胞市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第9章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第10章公司简介

  • PeproTech Inc.
  • Astellas Pharma Inc.
  • Merck KGaA
  • Lineage Cell Therapeutics Inc.
  • PromoCell GmbH
  • Thermo Fisher Scientific
  • ViaCyte, Inc.
  • Takara Bio Inc.
  • STEMCELL Technologies Inc
  • Cell Cure Neurosciences LTD
  • CellGenix GmbH
  • ESI BIO
  • Lonza
  • Kite Pharma
  • Cynata
  • Sumanas, Inc.
  • LifeCell
  • International Stem Cell Corporation
  • Genea BioCells
  • Geron
Product Code: SMRC24055

According to Stratistics MRC, the Global Human Embryonic Stem Cells Market is accounted for $1.8 billion in 2023 and is expected to reach $3.8 billion by 2030 growing at a CAGR of 11.2% during the forecast period. The inner cell mass of a human embryo during the blastocyst stage, usually 5-7 days after conception, is when human embryonic stem cells, a kind of pluripotent stem cell, are generated. The amazing capacity of these cells to develop into almost any form of cell in the human body is well recognized. They have a tremendous potential for application in regenerative medicine and research in addition to playing a critical function in early human development. It is crucial to ensure the efficacy and security of human embryonic stem-based therapeutics, to produce and deploy them, rigorous quality control procedures and safety evaluations are essential.

According to the article from DVC Stem published in August 2022, it was observed that the goal of stem cell therapy for Parkinson's disease is to replace destroyed brain cells with healthy, undifferentiated stem cells.

Market Dynamics:

Driver:

Growing technological advancements

The market for human embryonic stem cells has greatly benefited from technological improvements. With these developments, working with these cells has substantially improved in terms of effectiveness, safety, and usability, making them a more attractive alternative for research and possible therapeutic applications. Researchers can more accurately replicate the natural milieu of cells in the human body thanks to the development of three-dimensional (3D) culture models. As a result, human embryonic stem cells differentiation into certain cell types for regenerative therapy is improved. With the help of innovations like CRISPR-Cas9, the hESC genome may now be precisely edited, revolutionizing the field of gene editing. Hence all the above factors boost the market growth.

Restraint:

Concerns about the ethics of using embryonic stem cells

Studies looking into the therapeutic potential of embryonic stem cells (ESC) are linked to a number of moral dilemmas including the killing of human embryos. Lack of appropriate government laws that specify what can be supported in the development of therapies using embryo-based stem cells may eventually limit the market's growth to some extent. Federal laws are further necessary due to the complexity of the legislation in this field so that researchers, scientists, and pharmaceutical firms can develop ESC treatment and accelerate its commercialization.

Opportunity:

Rising incidence of chronic diseases

There is a high demand for efficient therapies due to the rising prevalence of chronic diseases including diabetes, cardiovascular disease, neurological disorders, and autoimmune ailments. These diseases, which frequently include permanent tissue damage, may be treated using human embryonic stem cells -based therapy. Tissue deterioration and organ dysfunction are frequently seen in patients with chronic illnesses and are a useful resource for tackling the long-term effects of chronic illnesses because regenerative medicine techniques use them to repair, replace, or regenerate damaged tissues and organs. To determine the safety and effectiveness of human embryonic stem-based treatments for particular chronic conditions, clinical studies have been started.

Threat:

Tendency of immune rejection

Immune rejection may cause human embryonic stem cells-derived cell treatments to fail. Transplanted cells may be attacked and killed if the immune system of the recipient recognizes them as alien, making the therapy useless and it may limit the long-term advantages of therapy based on human embryonic stem cells. Even if the initial engraftment is effective, the persistent immune response may cause the transplanted cells to gradually disappear, decreasing the therapeutic effect's longevity thus hampering the market growth.

COVID-19 Impact

The pandemic interfered with laboratory research projects, particularly stem cell projects. The development of human embryonic stem cells research and clinical trials was hampered by the temporary closure or reduction of activities at several research organizations. Moreover, the progress of these trials was slowed down by site closures, challenges with patient recruiting, and safety worries and made safety and efficacy of medical research and therapy development even more important. This might result in human embryonic stem cells -based medicines receiving more thorough safety evaluations which hinder the market growth.

The totipotent stem cells segment is expected to be the largest during the forecast period

The totipotent stem cells segment is estimated to have a lucrative growth, as these are special kind of stem cell and all cell types in the human body, including extraembryonic and embryonic tissues, may be formed from these cells, which is extraordinary. They vary from pluripotent stem cells, though, in that the latter can develop into all bodily cell types except for extraembryonic tissues. Understanding how totipotent stem cells develop into distinct cell types can be aided by research employing these cells.

The stem cell biology research segment is expected to have the highest CAGR during the forecast period

The stem cell biology research segment is anticipated to witness the highest CAGR growth during the forecast period, as these are living things that can develop into many kinds of cells. Various stem cell types are also employed in medical treatments. Numerous biopharmaceutical firms have recently conducted substantial research into these compounds, which have numerous uses at the clinical stage for a variety of disorders, including cancer and neurological ailments. Due to the growing frequency of disorders like Parkinson's disease, cancer, and others, stem cell biology research will see improved growth. The market under study is thus anticipated to see a significant growth rate throughout the projected period as a result of these reasons.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the growing government emphasis on drug discovery, healthcare investment, and advanced infrastructure for the development of technologies in drug discovery, as well as expanding development strategies used by several business verticals in the area. Furthermore, it is predicted that strict regulatory rules for medication research and related clinical studies would spur the market. The launch of biological and bio similar drugs by biopharmaceutical manufacturers in the US is another factor that is anticipated to fuel the market's expansion.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to stringent laws governing the use of human embryonic stem cells for both research and therapy. The creation and endorsement of stem cell-based medicines are regulated by national regulatory organizations and the European Medicines Agency (EMA). For instance, in Europe, human embryonic stem cells -based clinical studies have been carried out or are now being done for a range of illnesses, including spinal cord injury, heart disease, and degenerative diseases. The purpose of these trials is to assess the efficacy and safety of stem cell-based treatments. To advance human embryonic stem cells research and turn it into practical applications, partnerships between academic institutions, biotech firms, and healthcare facilities are typical in this region which encourages the market.

Key players in the market:

Some of the key players profiled in the Human Embryonic Stem Cells Market include: PeproTech Inc., Astellas Pharma Inc., Merck KGaA, Lineage Cell Therapeutics Inc., PromoCell GmbH, Thermo Fisher Scientific, ViaCyte, Inc., Takara Bio Inc., STEMCELL Technologies Inc, Cell Cure Neurosciences LTD, CellGenix GmbH, ESI BIO, Lonza, Kite Pharma, Cynata, Sumanas, Inc., LifeCell, International Stem Cell Corporation, Genea BioCells and Geron

Key Developments:

In October 2023, Astellas Pharma Inc. and BioLabs Global, Incand Mitsui Fudosan, announced that they have agreed on a tri-party memorandum of understanding to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan, world-renowned science hubs.

In October 2023, Merck launches new collaboration with United Nations-Guided Global Initiative on ageing to support carers; new training course provides critical skills for unpaid family carers and coincides with European Carers Day and Family Caregiver awareness month in the U.S.

In September 2023, Thermo Fisher Scientific expands St. Louis manufacturing for complex biologic treatments for diseases ranging from cancers to auto immune conditions to rare genetic disorders.

In September 2023, Thermo Fisher Scientific Inc. the world leader in serving science, and the National Minority Quality Forum (NMQF), an independent not-for-profit research and education organization, announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF's Alliance for Representative Clinical Trials (ARC).

Types Covered:

  • Totipotent Stem Cells
  • Pluripotent Stem Cells
  • Multipotent Stem Cells
  • Oligopotent Stem Cells
  • Unipotent Stem Cells
  • Other Types

Sources Covered:

  • Bone Marrow
  • Adult Body Tissues
  • Embryonic Tissues
  • Fetal tissues
  • Differentiated Somatic Cells
  • Other Sources

Applications Covered:

  • Stem Cell Biology Research
  • Regenerative Medicine
  • Tissue Engineering
  • Toxicology Testing
  • Blood Disease Treatment
  • Treatment of Cardiovascular Disease
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Human Embryonic Stem Cells Market, By Type

  • 5.1 Introduction
  • 5.2 Totipotent Stem Cells
  • 5.3 Pluripotent Stem Cells
  • 5.4 Multipotent Stem Cells
  • 5.5 Oligopotent Stem Cells
  • 5.6 Unipotent Stem Cells
  • 5.7 Other Types

6 Global Human Embryonic Stem Cells Market, By Source

  • 6.1 Introduction
  • 6.2 Bone Marrow
  • 6.3 Adult Body Tissues
  • 6.4 Embryonic Tissues
  • 6.5 Fetal tissues
  • 6.6 Differentiated Somatic Cells
  • 6.7 Other Sources

7 Global Human Embryonic Stem Cells Market, By Application

  • 7.1 Introduction
  • 7.2 Stem Cell Biology Research
  • 7.3 Regenerative Medicine
  • 7.4 Tissue Engineering
  • 7.5 Toxicology Testing
  • 7.6 Blood Disease Treatment
  • 7.7 Treatment of Cardiovascular Disease
  • 7.8 Other Applications

8 Global Human Embryonic Stem Cells Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 PeproTech Inc.
  • 10.2 Astellas Pharma Inc.
  • 10.3 Merck KGaA
  • 10.4 Lineage Cell Therapeutics Inc.
  • 10.5 PromoCell GmbH
  • 10.6 Thermo Fisher Scientific
  • 10.7 ViaCyte, Inc.
  • 10.8 Takara Bio Inc.
  • 10.9 STEMCELL Technologies Inc
  • 10.10 Cell Cure Neurosciences LTD
  • 10.11 CellGenix GmbH
  • 10.12 ESI BIO
  • 10.13 Lonza
  • 10.14 Kite Pharma
  • 10.15 Cynata
  • 10.16 Sumanas, Inc.
  • 10.17 LifeCell
  • 10.18 International Stem Cell Corporation
  • 10.19 Genea BioCells
  • 10.20 Geron

List of Tables

  • Table 1 Global Human Embryonic Stem Cells Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 4 Global Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 5 Global Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 6 Global Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 7 Global Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 8 Global Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 9 Global Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 10 Global Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 11 Global Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 12 Global Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 13 Global Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 14 Global Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 15 Global Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 16 Global Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 18 Global Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 19 Global Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 20 Global Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 21 Global Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 22 Global Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 23 Global Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 24 North America Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 North America Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 27 North America Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 28 North America Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 29 North America Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 30 North America Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 31 North America Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 32 North America Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 33 North America Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 34 North America Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 35 North America Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 36 North America Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 37 North America Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 38 North America Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 39 North America Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 40 North America Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 41 North America Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 42 North America Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 43 North America Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 44 North America Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 45 North America Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 46 North America Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 47 Europe Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 49 Europe Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 50 Europe Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 51 Europe Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 52 Europe Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 53 Europe Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 54 Europe Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 55 Europe Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 56 Europe Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 57 Europe Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 58 Europe Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 59 Europe Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 60 Europe Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 61 Europe Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 62 Europe Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 63 Europe Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 64 Europe Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 65 Europe Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 66 Europe Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 67 Europe Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 68 Europe Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 69 Europe Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 70 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 72 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 73 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 74 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 75 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 76 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 77 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 78 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 79 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 80 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 81 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 82 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 83 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 84 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 85 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 86 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 87 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 88 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 89 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 90 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 91 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 92 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 93 South America Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 95 South America Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 96 South America Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 97 South America Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 98 South America Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 99 South America Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 100 South America Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 101 South America Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 102 South America Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 103 South America Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 104 South America Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 105 South America Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 106 South America Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 107 South America Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 108 South America Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 109 South America Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 110 South America Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 111 South America Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 112 South America Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 113 South America Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 114 South America Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 115 South America Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 116 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 118 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 119 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 120 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 121 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 122 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 123 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 124 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 125 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 126 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 127 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 128 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 129 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 130 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 131 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 132 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 133 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 134 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 135 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 136 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 137 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 138 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)